fbpx
QQQ
+ 1.24
363.19
+ 0.34%
DIA
-0.53
351.15
-0.15%
SPY
+ 0.50
438.51
+ 0.11%
TLT
-0.84
150.48
-0.56%
GLD
+ 0.21
168.23
+ 0.12%

What 11 Analyst Ratings Have To Say About Vertex Pharmaceuticals

June 11, 2021 11:18 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Analysts have provided the following ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) within the last quarter:

Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago
Bullish 3 0 0 0
Somewhat Bullish 4 0 0 0
Indifferent 1 0 2 0
Somewhat Bearish 0 0 0 0
Bearish 0 0 0 0

In the last 3 months, 11 analysts have offered 12-month price targets for Vertex Pharmaceuticals. The company has an average price target of $258.91 with a high of $307.00 and a low of $205.00.

price target chart

This current average has decreased by 6.28% from the previous average price target of $276.27.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts can recommend “buy”, “sell”, “hold”, or similar verbage for each stock based on that company’s recent performance. “Buy” indicates that an analyst is optimistic about a stock’s short-term or mid-term growth and is a recommendation to purchase the stock. On the other hand, “Sell” implies that an analyst forecasts a downwards trend for the stock. “Hold” suggests that investors should maintain their positions on that stock because of forecasted stagnation or lack of new information.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.

Posted-In:

Analyst Ratings

Related Articles

Where Vertex Pharmaceuticals Stands With Analysts

Within the last quarter, Vertex Pharmaceuticals (NASDAQ:VRTX) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago read more

Expert Ratings For Vertex Pharmaceuticals

Within the last quarter, Vertex Pharmaceuticals (NASDAQ:VRTX) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago read more

UPDATE: SVB Leerink On Vertex Pharmaceuticals Downgrade: Firm Sees Biopharma Multiple Compression Occurring With Expectations Of >$10B To Supplement Internal Research Efforts & Portfolio; Projects FY1 Multiple Down Another 25% Over Coming Year

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021

  read more